HS-IT101 Injection in the Treatment of Advanced Solid Tumors - Trial NCT06342336
Access comprehensive clinical trial information for NCT06342336 through Pure Global AI's free database. This Phase 1 trial is sponsored by Qingdao Sino-Cell Biomedicine Co., Ltd. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 44 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Qingdao Sino-Cell Biomedicine Co., Ltd.
Timeline & Enrollment
Phase 1
Jan 18, 2024
Mar 31, 2028
Primary Outcome
Adverse Events (AE),Serious Adverse Events (SAE)
Summary
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with
 autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion
 preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the
 treatment of patients with advanced solid tumor.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06342336
Non-Device Trial